Abstract
Psoriasis has been for a long time a distressing skin disease difficult to treat. Several topical and systemic drugs have been used successfully in the treatment but the most active drugs are also the most difficult to manage in a long term treatment. Discovering the pathogenesis of this skin disorder has suggested that anti tumor necrosis factors agents could be an alternative treatment. Up to now several manuscripts show data supporting the idea that anti TNF are safe and effective more than other drugs. On the experience of dermatologists using this drug in a large number of patients TNF inhibitors are very effective drugs with a relatively safe management. At the moment several drug companies are developing a second generation of biologic drugs with different targets. This review point out the actual knowledge about anti TNF drugs and their activities on psoriasis both clinically and biologically.
Keywords: Psoriasis, therapy, anti TNF, biological agents, tumor necrosis factor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Volume: 8 Issue: 1
Author(s): D. Digiuseppe and C. Feliciani
Affiliation:
Keywords: Psoriasis, therapy, anti TNF, biological agents, tumor necrosis factor
Abstract: Psoriasis has been for a long time a distressing skin disease difficult to treat. Several topical and systemic drugs have been used successfully in the treatment but the most active drugs are also the most difficult to manage in a long term treatment. Discovering the pathogenesis of this skin disorder has suggested that anti tumor necrosis factors agents could be an alternative treatment. Up to now several manuscripts show data supporting the idea that anti TNF are safe and effective more than other drugs. On the experience of dermatologists using this drug in a large number of patients TNF inhibitors are very effective drugs with a relatively safe management. At the moment several drug companies are developing a second generation of biologic drugs with different targets. This review point out the actual knowledge about anti TNF drugs and their activities on psoriasis both clinically and biologically.
Export Options
About this article
Cite this article as:
Digiuseppe D. and Feliciani C., Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (1) . https://dx.doi.org/10.2174/187152309787580766
DOI https://dx.doi.org/10.2174/187152309787580766 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Gene Elements that Regulate Streptococcus pneumoniae Virulence and Immunity Evasion
Current Gene Therapy Headache in Multiple Sclerosis - Pharmacological Aspects
Current Pharmaceutical Design Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry L-Carnosine Modulates Respiratory Burst and Reactive Oxygen Species Production in Neutrophil Biochemistry and Function: May Oral Dosage Form of Non-Hydrolized Dipeptide L-Carnosine Complement Anti-Infective Anti-Influenza Flu Treatment, Prevention and Self-Care as an Alternative to the Conventional Vaccination?
Current Clinical Pharmacology Passive Immunization as Tool to Identify Protective HIV-1 Env Epitopes
Current HIV Research Lignans and Neolignans Anti-tuberculosis Identified by QSAR and Molecular Modeling
Combinatorial Chemistry & High Throughput Screening Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Synthesis and Biological Activities of New Halophenols
Medicinal Chemistry Molecular and Cellular Pathways as a Target of Therapeutic Hypothermia: Pharmacological Aspect
Current Neuropharmacology Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications
Current Pharmaceutical Design Complexities of Glucuronidation Affecting In Vitro-In Vivo Extrapolation
Current Drug Metabolism The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: The Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions
Current Gene Therapy Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design Chemistry and Pharmacology of Natural Catechins from <i>Camellia sinensis</i> as Anti-MRSA Agents
Current Topics in Medicinal Chemistry Novel Applications of Nanotechnology in Controlling HIV and HSV Infections
Current Drug Research Reviews